e-learning
resources
Munich 2014
Monday, 08.09.2014
Tuberculosis epidemiology: novel features
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The global risk of dying from multidrug-resistant tuberculosis (MDR-TB)
L. Brondi, D. Falzon, C. Sismanidis, P. Glaziou, M. Zignol, K. Floyd, H. Campbell, H. Nair (Edinburgh, United Kingdom; Geneva, Switzerland)
Source:
International Congress 2014 – Tuberculosis epidemiology: novel features
Session:
Tuberculosis epidemiology: novel features
Session type:
Oral Presentation
Number:
1694
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Brondi, D. Falzon, C. Sismanidis, P. Glaziou, M. Zignol, K. Floyd, H. Campbell, H. Nair (Edinburgh, United Kingdom; Geneva, Switzerland). The global risk of dying from multidrug-resistant tuberculosis (MDR-TB). Eur Respir J 2014; 44: Suppl. 58, 1694
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014
Analysis of multidrug-resistant tuberculosis
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1
Year: 2014
Risk factors for acquired drug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Epidemiology of TB
Source: Eur Respir Mon 2012; 58: 14-25
Year: 2012
Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Determinants of multidrug-resistant tuberculosis (MDR-TB) in Belarus
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia)
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
The MTBDRplus 2.0 for rapid diagnosis of multidrug-resistant tuberculosis among patients with high risk of TB resistance
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
Transmission of mycobacterium tuberculosis Ural 163-15 lineage causing multidrug-resistant tuberculosis among hospitalized patients
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015
Mutations in the genes of drug-resistant mycobacterium tuberculosis in Uzbekistan
Source: International Congress 2014 – Tuberculosis: diagnosis
Year: 2014
Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe
Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology
Year: 2016
Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk
Source: Eur Respir J 2012; 39: 1425-1431
Year: 2012
Linezolid in the treatment of patients with MDR TB and XDR TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
MDR-TB treatment outcomes in HIV positive patients
Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention
Year: 2014
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Risk factors for tuberculosis relapse in Polish patients
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Features of different M.tuberculosis strains that were isolated from MDR-TB patients in Kharkiv, Ukraine
Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept